Novartis patch gets approval at higher dose; I-Flow recalls delivery pump;

> The FDA has approved a higher dose of Novartis' Exelon Patch (transdermal rivastigmine) for the treatment of mild to moderate Alzheimer's disease. Press release

> While perhaps not the most instantly appealing route for drug delivery, Sophiris' PRX302, in development for benign prostatic hyperplasia, was well tolerated when dosed transrectally. Press release

> Coating drug-loaded particles with polyethylene glycol helps them ease further into the brain. Abstract

> I-Flow has recalled its ON-Q Pump with OnDemand Bolus Button, and the FDA says a malfunction in the device could lead to serious injury or death. Article

> Using microbubbles and ultrasound can disrupt the blood-brain barrier enough to get the cancer drug doxorubicin into rats' brains. Article | Abstract

> Arrowhead's ($ARWR) Calando Pharmaceuticals subsidiary has completed enrollment of its Phase Ib trial of CALAA-01, an RNAi therapeutic candidate targeting solid tumors. Press release

> Nordic NanoVector's Betalutin is slated to start clinical trials in non-Hodgkin's lymphoma in Sweden. Press release

> The T:slim pocket-sized insulin pump has started shipping in the U.S. Article

And Finally… Nanofactories could build drugs to order inside your body. Article